Polyplus now part of Sartorius’ Post

𝗣𝗼𝘄𝗲𝗿𝗳𝘂𝗹 𝗧𝗼𝗼𝗹𝘀 𝗳𝗼𝗿 𝗣𝗿𝗲𝗰𝗶𝘀𝗲 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗼𝗳 𝗩𝗶𝗮𝘁𝗲𝗹 𝗗𝗶𝗯𝗹𝗼𝗰𝗸 𝗡𝗮𝗻𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗦𝗶𝘇𝗲: 𝗣𝗼𝗹𝘆𝗺𝗲𝗿 𝗮𝗻𝗱 𝗦𝗼𝗹𝘃𝗲𝗻𝘁 𝗦𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 Nanomedicine has immense potential as it offers nanoparticle(NP)-based delivery vehicles for vaccines or APIs. Polymeric NPs have been used for drug delivery due to their biocompatibility, biodegradability and potential to provide customized properties by tailoring polymer chemistry. NP size is a critical factor that impacts circulation time, in vivo biodistribution and cell uptake[1-3]. Also, NPs < 200 nm can be sterile filtered. Thus, it is crucial to control NP size. Herein, we determined the most effective factors to control NP size. View the poster presented at CRS Bologna 2024 by Ashland: https://lnkd.in/dSARtTNz

High-Throughput Screening (HTS) Market worth $50.2 billion by 2029 Download PDF Brochure:-https://lnkd.in/dpaT2h8i The size of global high throughput screening market in terms of revenue was estimated to be worth $28.8 billion in 2024 and is poised to reach $50.2 billion by 2029, growing at a CAGR of 11.8% from 2024 to 2029. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Thermo Fisher Scientific Agilent Technologies, Merck Danaher Corporation Revvity, Tecan Bio-Rad Laboratories, Corning Incorporated Mettler-Toledo International, Inc Lonza Waters Corporation Sartorius Eppendorf Porvair plc Greiner AG & Co KG Charles River Laboratories Eurofins Scientific Finland Oy Hamilton Company Aurora Biomed Inc. Gilson BRAND GMBH + CO KG BMG LABTECH DIANA Biotechnologies, Creative Biolabs. HighRes Biosolutions. Biomat USA Axxam Sygnature Discovery Crown Bioscience . #highthroughputscreening #hts #drugdiscovery #biotech #pharmaresearch

Levitronix® Bioprocessing Conference Thursday, June 20th, 2024 Rapid progress in biotechnology is poised to change the world in the years to come. However, the ever-increasing complexity of medicine confronts bioprocessing with significant challenges. Novel manufacturing technologies such as Single-Use or Continuous Manufacturing are still in an early stage of implementation. We at Levitronix® believe that to build on the progress that the industry has made, end-users, system- and component suppliers must come together to reinforce what it takes to foster the trust and tight collaboration that are vital to the future success of bioprocessing. https://lnkd.in/gYPzrg4q

Register today for our webinar with Brian Hadley Principle Scientist and Marissa Dickson Scientist ll from Lonza Biologics as they discuss how an intensified process reduced COGs, improved titers and product quality. Don't miss this webinar!

We're proud to support Mesentech, a pioneering Vancouver-based biotech startup, to innovate targeted drug delivery with their cutting-edge small molecule therapeutics. Their first clinical program, aimed at promoting musculoskeletal tissue regeneration, is set to have a significant impact while minimizing organ toxicity.     Dr. Gang Chen, Director of Medicinal Chemistry at Mesentech, beautifully captures the value of using ChemAIRS from Chemical.AI: “𝘜𝘵𝘪𝘭𝘪𝘻𝘪𝘯𝘨 𝘊𝘩𝘦𝘮𝘈𝘐𝘙𝘚 𝘧𝘳𝘰𝘮 𝘊𝘩𝘦𝘮𝘪𝘤𝘢𝘭.𝘈𝘐 𝘪𝘴 𝘢𝘯𝘢𝘭𝘰𝘨𝘰𝘶𝘴 𝘵𝘰 𝘪𝘯𝘤𝘰𝘳𝘱𝘰𝘳𝘢𝘵𝘪𝘯𝘨 𝘢 𝘤𝘩𝘦𝘮𝘪𝘴𝘵 𝘸𝘪𝘵𝘩 𝘥𝘦𝘤𝘢𝘥𝘦𝘴 𝘰𝘧 𝘦𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦 𝘪𝘯𝘵𝘰 𝘺𝘰𝘶𝘳 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘵𝘦𝘢𝘮. 𝘛𝘩𝘦𝘴𝘦 𝘴𝘶𝘨𝘨𝘦𝘴𝘵𝘦𝘥 𝘳𝘦𝘢𝘤𝘵𝘪𝘰𝘯𝘴 𝘢𝘳𝘦 𝘤𝘩𝘦𝘮𝘪𝘤𝘢𝘭𝘭𝘺 𝘱𝘭𝘢𝘶𝘴𝘪𝘣𝘭𝘦, 𝘵𝘩𝘰𝘶𝘨𝘩 𝘵𝘩𝘦𝘺 𝘮𝘢𝘺 𝘯𝘰𝘵 𝘩𝘢𝘷𝘦 𝘣𝘦𝘦𝘯 𝘱𝘳𝘦𝘷𝘪𝘰𝘶𝘴𝘭𝘺 𝘦𝘮𝘱𝘭𝘰𝘺𝘦𝘥 𝘵𝘰 𝘴𝘺𝘯𝘵𝘩𝘦𝘴𝘪𝘻𝘦 𝘴𝘪𝘮𝘪𝘭𝘢𝘳 𝘤𝘰𝘮𝘱𝘰𝘶𝘯𝘥𝘴".    By leveraging ChemAIRS' advanced retrosynthesis and condition search capabilities, Mesentech is speeding up the creation of innovative synthetic routes, optimizing processes with cost-effective materials, and significantly reducing waste. The flexibility of ChemAIRS empowers their chemists to quickly adapt to project needs, ensuring that every step from concept to execution is as efficient and effective as possible. Read the full case study below.    #Biotech #Innovation #AI #DrugDevelopment #ChemicalAI #Mesentech #SyntheticChemistry #Pharma

The latest issue of ChemieXtra features an in-depth report on our SBS 300 Robotic. The SBS 300 Robotic enables the simultaneous processing of two microtiter plates and excels in efficiency and precision. Its modularity and flexible integration make it a valuable tool in the fields of pharmaceuticals, biotechnology, food analysis, and environmental science. Learn more about how this innovative centrifuge can optimize your laboratory workflows in the latest ChemieXtra issue: https://lnkd.in/d7XB6NjY #LabTechnology #Pharmaceuticals #Biotechnology #FoodAnalysis #EnvironmentalScience #LabEquipment #Innovation #Research #ChemieXtra #Hettich #Centrifuge #SBS300 #LabEfficiency #ScientificResearch #LabAutomation #MicrotiterPlates

High-Throughput Screening (HTS) Market worth $50.2 billion by 2029 Download PDF Brochure:-https://lnkd.in/dnn6jtvM The size of global high throughput screening market in terms of revenue was estimated to be worth $28.8 billion in 2024 and is poised to reach $50.2 billion by 2029, growing at a CAGR of 11.8% from 2024 to 2029. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Thermo Fisher Scientific Agilent Technologies, Merck Danaher Corporation Revvity. TECAN GROUP AG-REG Bio-Rad Laboratories, Corning Incorporated Mettler-Toledo International, Inc Lonza Waters Corporation Sartorius Eppendorf Porvair plc Greiner AG & Co KG Charles River Laboratories Eurofins Scientific Finland Oy Hamilton Company Aurora Biomed Inc. Gilson Brand Trust GmbH BMG LABTECH DIANA Biotechnologies, Creative Biolabs. HighRes Biosolutions. Biomat USA Axxam Sygnature Discovery Crown Bioscience #highthroughputscreening #drugdiscovery #biotechnology #htstechnology #pharmaresearch

📘 Just Released: Dolomite’s Application Note on Advanced Droplet Generation for Drug Discovery and Molecule Encapsulation We're proud to publish an Application Note that epitomizes the capabilities of the Dolomite Mitos System. This detailed guide provides invaluable insights into the precision engineering of water droplets in FluoSurf carrier phases, showcasing our system's proficiency in creating a wide array of droplet sizes. ✨ Whether creating monodisperse droplets or encapsulating delicate biomolecules or microparticle generation, the Dolomite Mitos System is synonymous with unparalleled precision and control for academic and industry labs alike. Elevate your research precision today by exploring the full application note. Discover how Dolomite is driving forward the boundaries of scientific exploration and innovation. 🔗 https://lnkd.in/eCbUYgqm #Microfluidics #PrecisionEngineering #ResearchAndDevelopment #Science #microparticles #DrugDiscovery #Diagnostics #Pharmaceuticals #Biotech #Microencapsulation #Droplets

High-Throughput Screening (HTS) Market worth $50.2 billion by 2029 Download PDF Brochure:-https://lnkd.in/dwhPYC8T The size of global high throughput screening market in terms of revenue was estimated to be worth $28.8 billion in 2024 and is poised to reach $50.2 billion by 2029, growing at a CAGR of 11.8% from 2024 to 2029. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Thermo Fisher Scientific Agilent Technologies, Merck KGaA, Darmstadt, Germany Danaher Corporation Revvity TECAN GROUP AG-REG Bio-Rad Laboratories, Corning Incorporated Mettler-Toledo International, Inc Lonza Waters Corporation Sartorius Eppendorf Porvair plc Greiner AG & Co KG Charles River Laboratories Eurofins Scientific Finland Oy Hamilton Company Aurora Biomed Inc. Gilson BMG LABTECH DIANA Biotechnologies, Creative Biolabs. HighRes Biosolutions. Biomat Srl | Coated 96 Well Plates for ELISA & other Immunoassays & PCR Tubes and Plates, Axxam Sygnature Discovery Crown Bioscience . #highthroughputscreening #drugdiscovery #biotech #hts #pharmatech

Aragen Bioscience recently partnered with Sweden-based Getinge to diagnose and trouble-shoot challenges arising during scale-up from bench scale to production scale. In our quest to enhance our capabilities, we've integrated Getinge's state-of-the-art single-use production reactors (SUPRs) into our operations. To meet the demands of larger-scale production runs required for preclinical studies, we embarked on a trial with Getinge. By adopting their 50 L and 250 L SUPRs, we aimed to amplify our production volumes, facilitating faster preclinical production processes. During the trial, Aragen’s model fed-batch process was successfully scaled up from a 2 L STR to 50 L and 250 L SUPRs (Single Use Production Reactors). Unlike conventional multi-use reactors, SUPRs are more efficient because they can be set up instantly and also have a lower risk of cross-contamination. Click here to read the full details of the study https://lnkd.in/ghyTr7QK Meet our team at the upcoming PEGS Boston event from 13th -17th  May, 2024, at Omni Boston Hotel, Sea port, booth no. 710 to discuss how Aragen can use the Getinge SUPRs to accelerate your bioproduction process. Keshav Vasanthavada Lakshman Rajagopalan Subodh Deshmukh #bioreactors #journey #bioproduction #drugmanufacturing #preclinical #sweden #boston #drugdevelopment #events2024 #aragen #endtoendsolutions #largemolecules #biologics #california